JPRN-UMIN000049022
Recruiting
未知
Efficacy and safety of Immune check point inhibitors in patients with non-small cell lung cancer harboring rare driver oncogene - Efficacy and safety of Immune check point inhibitors in patients with non-small cell lung cancer harboring rare driver oncogene
orth East Japan Study Group0 sites870 target enrollmentSeptember 26, 2022
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- orth East Japan Study Group
- Enrollment
- 870
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\) Patients who are judged by the principal investigator or sub\-investigator to be inappropriate for participation in this study. (2\) Patients who had no driver mutation/translocation or EGFR mutation only.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Efficacy and safety of immune checkpoint inhibitors alone or in combination with chemotherapy in pulmonary sarcomatoid carcinomaPulmonary sarcomatoid carcinomaJPRN-UMIN000046002Kobe University124
Completed
Not Applicable
The usefulness of immune checkpoint inhibitors among lung cancer patients with driver gene mutantsung cancerJPRN-UMIN000040789Yokohama City University
Completed
Not Applicable
Efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer other than adenocarcinoma or squamous cell carcinoma: multicenter retrospective observational studyon-small cell lung cancer other than adenocarcinoma or squamous cell carcinomaJPRN-UMIN000037777Hamamatsu University School of Medicine60
Not yet recruiting
Not Applicable
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy has an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.NL-OMON25676Erasmus MC390
Active, not recruiting
Phase 1
Patient preference for administration of cancer immunotherapy via an elastomeric pump. A patient preference study and an economic analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy is an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-000058-24-NLErasmus MC Cancer Institute390